Tag: Sanofi

U.S. jury upheld validity of two patents for Amgen Inc’s cholesterol-lowering drug Repatha® (evolocumab)

US healthcare giant Amgen has successfully defended two of its patents related to cholesterol-lowering drug Repatha® (evolocumab). Amgen announced on February 25, 2019 that a U.S. District Court jury in Delaware delivered a verdict in the company’s favor upholding the validity of two patents related to its anti-cholesterol drug, Repatha®. The patent challenge was brought … Continue reading U.S. jury upheld validity of two patents for Amgen Inc’s cholesterol-lowering drug Repatha® (evolocumab)

Read more »